Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of deferasirox for iron overload after HSCT in beta-thalassemia major
2016-001561-88Phase 2
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in iron overload and beta thalassemia, sponsored by Novartis. Primary endpoint: Safety of deferasirox.
02
Drugs
deferasirox
03
Conditions
iron overloadbeta thalassemia
Beyond the preview
Go deeper on 2016-001561-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001561-88.